{ "ok": true, "cik": "1725430", "ticker": "INBS", "name": "INTELLIGENT BIO SOLUTIONS INC.", "filings": [ { "form": "8-K", "filed": "2026-09-11", "items": [ "8.01 Other Events" ], "url": "https://www.sec.gov/Archives/edgar/data/1725430/000149315226042411/0001493152-26-042411-index.htm" }, { "form": "8-K", "filed": "2026-09-09", "items": [ "7.01 Regulation FD Disclosure", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1725430/000149315226041901/0001493152-26-041901-index.htm" }, { "form": "8-K", "filed": "2026-09-02", "items": [ "1.01 Entry into a Material Definitive Agreement", "3.02 Unregistered Sales of Equity Securities", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1725430/000149315226041253/0001493152-26-041253-index.htm" }, { "form": "8-K", "filed": "2026-09-01", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1725430/000149315226041055/0001493152-26-041055-index.htm" }, { "form": "8-K", "filed": "2026-08-28", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1725430/000149315226040656/0001493152-26-040656-index.htm" }, { "form": "8-K", "filed": "2026-08-19", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1725430/000149315226039140/0001493152-26-039140-index.htm" } ], "events12m": 34, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001725430.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1725430" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up INTELLIGENT BIO SOLUTIONS INC. ($INBS). Last filing: 8-K (8.01 Other Events), 2026-09-11. 34 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2026-06-30", "revenue": 4215175, "revenueGrowth1y": 0.3808782348555233, "revenueGrowthPerYear": 0.7621678572149382, "yearsOfData": 5, "operatingMargin": -2.9911178064967645, "operatingMarginPrior": -3.498458984213761, "netMargin": -2.9580437348390043, "operatingCashFlow": -11927222, "capitalSpending": 125731, "freeCashFlow": -12052953, "researchAndDevelopment": null, "researchShareOfRevenue": null, "cash": 3992312, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2022-06-30", "revenue": 437146 }, { "fiscalYearEnd": "2023-06-30", "revenue": 1256872 }, { "fiscalYearEnd": "2024-06-30", "revenue": 3111781 }, { "fiscalYearEnd": "2025-06-30", "revenue": 3052532 }, { "fiscalYearEnd": "2026-06-30", "revenue": 4215175 } ], "totalEquity": 5510835, "totalAssets": 11941836, "equityRatio": 0.46147300967790883, "returnOnEquity": -2.262574001943444, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "range80": { "low": 4451132.231310142, "high": 7992508.590299095, "baseline": 6065039.148807934, "n": 749, "band": "b00" }, "ifPaceHeld": { "low": 4451132.231310142, "high": 7992508.590299095 } }, "edgarette": "🔖 Exposure: revenue $4.2M (FY2026). Experience: revenue up 38.1% on the year, up 76.2% a year over 4 years; operating margin -299.1%, up from -349.8%. Soundness: equity 46.1% of assets, return on equity -226.3%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $4.5M and $8.0M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A range, not a forecast. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -299.1% against a 1.2% median; growth 38.1% against 11.6%.", "peers": { "sic": 3841, "sicDescription": "Surgical & Medical Instruments & Apparatus", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "3841", "growth": [ 0.1161, 60 ], "opMargin": [ 0.0124, 60 ], "equityRatio": [ 0.5291, 59 ], "returnOnEquity": [ -0.0233, 55 ], "payoutRatio": [ 0.3812, 8 ] }, "summary": "Intelligent Bio Solutions (INBS) grew revenue 38.1% in FY2026 to $4 million, operating margin -299% against a 1.2% median for surgical & medical instruments & apparatus, equity 46.1% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
INTELLIGENT BIO SOLUTIONS INC. against its own record and its peers
Operating marginPeer median 1.2%-299.1%Revenue, on the yearPeer median 11.6%38.1%Equity of assetsPeer median 52.9%46.1%Return on equityPeer median -2.3%-226.3%Gold tick: the median of 55–59 peers with $50M+ revenue in surgical & medical instruments & apparatus
", "chartHorizon": null, "backtest": { "tests": 3, "hits": 2, "rate": 0.6666666666666666, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T15:23:08.823Z", "hash": "bad3f0206baf9610", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Intelligent Bio Solutions (INBS) grew revenue 38.1% in FY2026 to $4 million, operating margin -299% against a 1.2% median for surgical & medical instruments & apparatus, equity 46.1% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2026-06-30", "revenue": 4215175, "totalDebt": null, "cash": 3992312 }, "experience": { "revenueGrowth1y": 0.3808782348555233, "revenueGrowthPerYear": 0.7621678572149382, "operatingMargin": -2.9911178064967645, "operatingMarginPrior": -3.498458984213761, "netMargin": -2.9580437348390043, "freeCashFlow": -12052953 }, "soundness": { "equityRatio": 0.46147300967790883, "returnOnEquity": -2.262574001943444, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 3841, "sicDescription": "Surgical & Medical Instruments & Apparatus", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "3841", "growth": [ 0.1161, 60 ], "opMargin": [ 0.0124, 60 ], "equityRatio": [ 0.5291, 59 ], "returnOnEquity": [ -0.0233, 55 ], "payoutRatio": [ 0.3812, 8 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "range": { "low": 4451132.231310142, "high": 7992508.590299095, "baseline": 6065039.148807934, "coverage": 0.8, "method": "v3", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); range = 10th to 90th percentile of how SEC company-years of the same size band actually turned out", "calibratedOn": { "companyYears": 749, "sizeBand": "b00" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 3, "hits": 2, "rate": 0.6666666666666666, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T15:23:08.823Z", "hash": "bad3f0206baf9610", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001725430.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1725430" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }